DERMOCOS: Study in Patients With Solid Tumor Regarding Access to Dermo-cosmetics and Aesthetic Solutions
Study Details
Study Description
Brief Summary
Cancer treatments can trigger cutaneous side-effects, as well as nail and hair toxicities. When related to drug treatment, this iatrogeny depends on the type of drug, its dosage and individual susceptibility. Although these dermatological adverse events are rarely serious, they can significantly alter patients' quality of life, and may even necessitate the introduction of curative treatment.
The impact of these side effects can be mitigated by the use of dermo-cosmetic products and aesthetic solutions. However, most of this supportive care is not reimbursed by the health insurance system, representing a source of inequalities in access to healthcare for cancer patients.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
This study aims at establishing, in a cohort of patients with solid tumors, the state of their knowledges, given information and their financial capacities regarding access to dermo-cosmetics and aesthetic solutions, that are used in the attenuation of cancer treatments' side-effects.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Patients with Digestive System Cancer
|
Other: Questionnaires
25-items questionnaire
|
| Patients with Head and Neck Cancer
|
Other: Questionnaires
25-items questionnaire
|
| Patients with Breast Cancer
|
Other: Questionnaires
25-items questionnaire
|
| Patients with Nervous System Tumors
|
Other: Questionnaires
25-items questionnaire
|
| Patients with Urological Cancer
|
Other: Questionnaires
25-items questionnaire
|
| Patients with Lung Cancer
|
Other: Questionnaires
25-items questionnaire
|
| Patients with Gynecologic Cancer
|
Other: Questionnaires
25-items questionnaire
|
Outcome Measures
Primary Outcome Measures
- Describe patients' knowledges regarding cutaneous side-effects, nail and hair toxicities induced by anticancer drugs [at inclusion]
4 items questionnaires
- Describe patients' knowledges regarding dermo-cosmetics and aesthetic solutions that can attenuate cutaneous side-effects, nail and hair toxicities induced by anticancer drugs [at inclusion]
10 items questionnaires
Secondary Outcome Measures
- Describe patients' socio-economic profile to assess equity regarding access to dermo-cosmetics and aesthetic solutions [at inclusion]
11 items questionnaires
- Correlate patients' knowledge level depending on tumoral location [at inclusion]
Tumoral location as described in medical chart
- Correlate patients' knowledge level depending on received treatment [at inclusion]
Type of chemotherapy administered on the day of inclusion as described in medical chart
- Correlate patients' knowledge level depending on treatment phase [at inclusion]
Type of treatment phase (i.e. neoadjuvant, adjuvant, 1st or 2nd metastatic line) as described in medical chart
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Age > 18 years
-
Patients with solid tumors (eligible localization include: digestive system, Head and Neck, Breast, Brain, Lung Tumors, Urological and Gynecologic cancers)
-
Patients able to read and understand French
-
Patients that has expressed their consent and with signed consent form
Exclusion Criteria:
-
Minor or patients placed under guardianship or supervision
-
Patients unable to read French
-
Patients placed under judicial protection
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Institut de cancérologie Strasbourg Europe | Strasbourg | France | 67033 |
Sponsors and Collaborators
- Institut de cancérologie Strasbourg Europe
Investigators
- Study Chair: Nelly ETIENNE-SELLOUM, PharmD, Institut de cancérologie Strasbourg Europe
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 2023-001
- 2023-A00546-39